Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 4 records in total 4
    records per page




    High prevalence SERO of deep venous thrombosis HP deep venous thrombosis MESHD in non-severe COVID-19 patients hospitalized for a neurovascular disease MESHD

    Authors: Olivier Rouyer; Irene-Nora Pierre-Paul; Amadou Balde; Damaris Jupitet; Daniela Bindila; Bernard Geny; Valerie Wolff

    doi:10.1101/2020.09.03.20187344 Date: 2020-09-05 Source: medRxiv

    Abstract Introduction: Severe SARS-CoV-2 infection MESHD, responsible for COVID-19, is accompanied by venous thromboembolic MESHD events particularly in intensive care unit. In non-severe COVID-19 patients affected by neurovascular diseases MESHD, the prevalence SERO of deep venous thrombosis HP deep venous thrombosis MESHD ( DVT MESHD) is unknown. The aim of or study was to report data obtained after systematic Doppler ultrasound scanning ( DUS MESHD) of lower limbs in such patients. Methods: Between March 20 and May 2, 2020, consecutive patients with neurovascular diseases MESHD with non-severe COVID-19 were investigated with a systematic bedside DUS. Results Thirteen patients were enrolled including 10 acute ischemic strokes MESHD ischemic strokes HP, one transient ischemic attack HP ischemic MESHD attack, one cerebral venous thrombosis HP cerebral venous thrombosis MESHD and one haemorrhagic stroke MESHD stroke HP. At admission, the median National Institute of Health Stroke HP Stroke MESHD Scale (NIHSS) was of 6 (IQR, 0-20). We found a prevalence SERO of 38.5% of asymptomatic TRANS calves DVT MESHD (n=5) during the first week after admission despite thromboprophylaxis. Among them, one patient had a symptomatic pulmonary embolism HP pulmonary embolism MESHD. Two patients died during hospitalization but the outcome was favourable in the others with a discharge median NIHSS of 1 (IQR, 0-11). Discussion/Conclusion: Despite thromboprophylaxis, systematic bedside DUS showed a high prevalence SERO of 38.5% of DVT MESHD in non-severe COVID-19 patients with neurovascular diseases MESHD. Therefore, we suggest that this non-invasive investigation should be performed in all patients of this category.

    Incidence of thromboembolism HP thromboembolism MESHD in patients with COVID-19: a systematic review and meta-analysis

    Authors: Kochawan Boonyawat; Pichika Chantrathammachart; Pawin Numthavej; Nithita Nanthatanti; Sithakom Phusanti; Angsana Phuphuakrat; Pimjai Niparuck; Pantep Angchaisuksiri

    doi:10.21203/rs.3.rs-63530/v1 Date: 2020-08-21 Source: ResearchSquare

    Background Since the beginning of the coronavirus disease MESHD 2019 (COVID-19) pandemic, the incidence of thromboembolism HP thromboembolism MESHD has been increasingly reported. The aim of this systematic review was to explore the incidence of venous and arterial thromboembolism MESHD thromboembolism HP among COVID-19 patients requiring hospitalization.Methods Medline, Embase, Scopus, and grey literature were searched until May 2020. Observational studies reported on the incidence of venous thromboembolism MESHD thromboembolism HP ( VTE MESHD), including pulmonary embolism HP pulmonary embolism MESHD ( PE MESHD) and deep vein thrombosis MESHD ( DVT MESHD) or arterial thromboembolism MESHD thromboembolism HP ( ATE MESHD) were included. The pool incidences and their 95% confidence intervals (CI) were calculated using the random-effects model.Results A total of 26 studies were included. In the intensive care unit (ICU) setting, the pooled incidence of VTE MESHD was 27% (95% CI, 20–35%). Subgroups based on compression ultrasound (CUS) screening revealed a higher incidence of DVT MESHD in the CUS screening group than in the no CUS screening group (27% [95% CI, 20–35%] vs. 3% [95% CI, 1–5%]). The pooled incidence of ATE MESHD in ICU was 3% (95% CI, 2–4%). In the non-ICU setting, the pooled incidence of VTE MESHD was 8% (95% CI, 4–12%,).Conclusions The incidence of VTE MESHD in COVID-19 patients was higher in the ICU setting than in the non-ICU setting, and also significantly higher in studies that incorporated the CUS screening protocol. The incidence of ATE MESHD in the ICU setting was low. VTE MESHD prophylactic measures should be given to all hospitalized patients diagnosed with COVID-19, especially in the ICU setting.

    Acute Pulmonary Embolism HP Pulmonary Embolism MESHD in Critically Ill Patients with COVID-19

    Authors: Madhura Manjunath; Julio Miranda; Liana Fraenkel; Paul Manje Johansen; Blessing Phinney; Georgianne Valli-Harwood; Cynthia Callahan; Hafez Alsmaan; David Oelberg

    doi:10.1101/2020.05.22.20110270 Date: 2020-05-24 Source: medRxiv

    Since the discovery of the novel coronavirus ( SARS-Co-V-2 MESHD) in December 2019, multiple characteristics have been reported, as our understanding of this new disease unfolds. One such association is its tendency to cause thromboembolic MESHD events, particularly venous thromboembolism MESHD thromboembolism HP (1,2). In a four-week period during the initial spread of COVID-19 at a 300 bed community hospital in western Massachusetts, 23 patients who were PCR positive for SARS-CoV-2 RNA required treatment in either the intensive care unit (ICU) or intermediate/step-down unit (SDU). All patients were treated with standard DVT prophylaxis from the time of admission, except for two patients who were on full anticoagulation for chronic atrial fibrillation HP atrial fibrillation MESHD. Of the 23 patients, 7 (30%) were diagnosed with acute, clinically significant, pulmonary embolism HP pulmonary embolism MESHD ( PE MESHD). Four of the 7 manifested evidence of acute cor pulmonale MESHD cor pulmonale HP, one of whom succumbed as a direct consequence of a massive PE MESHD. Other markers were reviewed in the 7 patients to identify trends that could allow for early suspicion of PE MESHD in COVID-19 patients. Although D-dimer tended to rise during the hospitalization relative to the control group, the results were inconsistent, and there were no other meaningful distinguishing features between the groups at the time of admission.

    COVID-19 in Elderly TRANS Patient: A Case Report

    Authors: Zheng Qin; Xingjian Wang; Wei Wang

    doi:10.21203/rs.3.rs-27253/v1 Date: 2020-05-06 Source: ResearchSquare

    Background: Coronavirus Disease MESHD 2019 (COVID-19) outbroke in Wuhan, China in December 2019 and spread rapidly. Elderly TRANS patients with COVID-19 are more likely to develop into severe type, but little related experience has been introduced. Case presentation: An 82-year-old female TRANS patient living in Wuhan, China was referred because of fever HP fever MESHD, dry cough MESHD cough HP and chest distress for a week. Clinical diagnosis of COVID-19 was considered, confirmed by viral nucleic acid detection. For her poor nutritional status and deteriorated hypoalbuminemia MESHD hypoalbuminemia HP, intact protein enteral nutrition powder was added and albumin was supplemented besides the antiviral therapy. Her fever HP fever MESHD gradually subsided with the alleviation of related symptoms. During her hospitalization, D-dimer level elevated with ultrasonographically detected thromboembolism HP thromboembolism MESHD in bilateral gastrocnemius veins, and low molecular weight heparin was thereby administrated for the prevention of pulmonary embolism HP pulmonary embolism MESHD. Conclusions: The experience of this case suggested that the timely screening and intervention of malnutrition HP malnutrition MESHD and venous thromboembolism MESHD thromboembolism HP are crucial issues to be concerned when treating elderly TRANS patients with severe COVID-19 besides the routine antiviral therapy. 

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.